-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HaAU9wJOZe5ZFiiBchEbJjavC1VPeN/VrPdj2zWnkbUzCLt8FIxtlu9gCnyz02gd 5v/fyy3+V0PefXJf7rDSaA== 0001144204-04-013510.txt : 20040830 0001144204-04-013510.hdr.sgml : 20040830 20040830151935 ACCESSION NUMBER: 0001144204-04-013510 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20040830 ITEM INFORMATION: Other Events FILED AS OF DATE: 20040830 DATE AS OF CHANGE: 20040830 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RITA MEDICAL SYSTEMS INC CENTRAL INDEX KEY: 0001056421 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943199149 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30959 FILM NUMBER: 041005303 BUSINESS ADDRESS: STREET 1: 967 N SHORELINE BLVD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94013 BUSINESS PHONE: 6503858500 MAIL ADDRESS: STREET 1: 967 NORTH SHORELINE BLVD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 8-K 1 form8k.htm Unassociated Document

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

August 30, 2004
Date of Report
(Date of earliest event reported)


RITA Medical Systems, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

 000-30959

 94-3199149

(Commission File Number)

(I.R.S. Employer Identification No.)

               
   

967 N. Shoreline Blvd.
Mountain View, CA 94043
(Address of principal executive offices, with zip code)

(650) 314-3400
(Registrant's telephone number, including area code)





Item 8.01. Other Events and Required FD Disclosure.

On August 30, 2004, RITA Medical Systems, Inc., a Delaware corporation ("RITA"), announced that Mr. Darrin Uecker will be assuming responsibility for the company’s operations, and that Mr. Trent Reutiman has been named Vice President of Sales and Marketing. Further, Mr. Robert Wenzel will be leaving the Company. A copy of RITA’s press release announcing these changes is attached as Exhibit 99.1 hereto and incorporated by reference herein.

 
 

 




SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    RITA Medical Systems, Inc.

 

Date: August 30, 2004            By:  /s/ Donald Stewart                                      
  Donald Stewart, Chief Financial Officer and
     Vice President Finance and Administration


 

 



RITA MEDICAL SYSTEMS, INC.

INDEX TO EXHIBITS


Exhibit Number
Description
 
99.1
Press Release of RITA Medical Systems, Inc. dated August 30, 2004.
 


 
 
 
 
 
 
EX-99.1 2 ex99_1.htm Unassociated Document



 

Contact:          Allen & Caron Inc.          RITA Medical Systems, Inc.
Matt Clawson (investors)       Don Stewart, Chief Financial Officer
949-474-4300       Stephen Pedroff, VP Marketing Communications
matt@allencaron.com     650-314-3400   
SurfMedia Communications           dstewart@ritamed.com
Juliana Minsky (media)                   spedroff@ritamed.com
805-962-3700
jm@surfmedia.com


RITA MEDICAL SYSTEMS ANNOUNCES COMPLETION OF EXECUTIVE TEAM INTEGRATION FOLLOWING MERGER

Darrin Uecker, CTO, Assumes Operations Responsibilities, Trent Reutiman Named Vice President, Sales and Marketing

Mountain View, Calif., August 30, 2004—RITA Medical Systems, Inc. (Nasdaq: RITA), a leader in medical oncology devices, today announced that RITA Chief Technology Officer, Mr. Darrin Uecker, will assume all operations responsibilities for the company, and that Mr. Trent Reutiman has been named Vice President, Sales and Marketing. Mr. Uecker will assume the operations responsibilities of Mr. Robert Wenzel, who is leaving the company to pursue other opportunities.

Mr. Joseph DeVivo, President and Chief Executive Officer of RITA Medical commented, "I am extremely pleased with the progress we have made integrating our vascular access and radiofrequency ablation businesses. We will continue to focus on delivering the best technology in the market and on developing the best sales and marketing organization in the category. I am confident that we have an excellent team in place to build RITA into a world leader in the medical oncology device market."

Mr. Uecker will lead the company’s operations functions, assuming all of the operations responsibilities for the company’s vascular access products (VAP). In addition, Mr. Uecker will have overall responsibility for research and development, clinical affairs, quality assurance, and all regulatory activities. Prior to joining RITA, Mr. Uecker was Chief Operating Officer at Computer Motion, a Santa Barbara based developer of robotic surgical systems. Mr. Uecker led that company’s integration efforts during the 2003 merger with Intuitive Surgical, a Sunnyvale based maker of surgical robotic systems. Since the announcement of the merger between RITA Medical and Horizon Medical, Mr. Uecker has led the integration of the Mountain View, California and Manchester, Georgia operations and is responsible for completing the relocation of manufacturing of the company’s radiofrequency ablation (RFA) products to the Georgia facility. Mr. Uecker reports directly to Mr. DeVivo.

Mr. Uecker commented, "The responsiveness and professionalism of the staff in Manchester has been extremely gratifying. They have proven that they have the ability to make the transition to manufacturing both product lines at the facility very smooth. We expect to complete the transition on or ahead of our intended schedule in the first quarter of next year."

MORE-MORE-MORE

RITA MEDICAL SYSTEMS ANNOUNCES EXECUTIVE TEAM INTEGRATION
2-2-2

Mr. DeVivo commented, "Darrin played an important role in identifying and securing cost synergies associated with combining manufacturing operations in our Georgia facility. I look forward to his expanded role in the organization, and I wish to thank Bob Wenzel for his support and leadership during the merger process."
As the company’s new Vice President of Sales and Marketing, Mr. Reutiman will lead the company’s sales and marketing activities, assuming responsibility for the more than 60 full time sales and marketing employees. During his tenure at RITA Medical Mr. Reutiman has had responsibility for the company’s domestic sales staff, and he will now also assume responsibility for the domestic marketing functions of the organization.

Mr. Reutiman commented, "With the integration of the sales force complete, I am very pleased to report that we have retained the top sellers from both organizations and the new team is now very active in the field. We have structured the compensation program at RITA to engage our sellers in the process of continuing to develop the marketplace and I have dedicated two senior sales people to training roles in order to raise the competency of the entire sales and marketing organization."

Mr. DeVivo commented, "Trent has done an excellent job of managing the sales force, delivering solid and consistent growth in the RFA business for the past four quarters. I am confident that he will do an equally outstanding job managing our greatly expanded team of sales and marketing professionals. I look forward to his continued contribution to the growth of RITA Medical."


About RITA Medical Systems, Inc.
RITA Medical Systems develops, manufactures and markets innovative products for cancer patients including radiofrequency ablation (RFA) systems for treating cancerous tumors as well as percutaneous vascular and spinal access systems. The Company's oncology product lines include implantable ports, some of which feature its proprietary Vortex® technology; tunneled central venous catheters; safety infusion sets and peripherally inserted central catheters used primarily in cancer treatment protocols. The proprietary RITA system uses radiofrequency energy to heat tissue to a high enough temperature to ablate it or cause cell death. In March 2000, RITA became the first RFA company to receive specific FDA clearance for unresectable liver lesions in addition to its previous general FDA clearance for the ablation of soft tissue. In October 2002, RITA again became the first company to receive specific FDA clearance, this time, for the palliation of pain associated with metastatic lesions involving bone.

 
The statements in this news release related to the integration of the Company’s vascular access and radiofrequency ablation business, the development of the vascular access and radiofrequency markets, the growth of the Company’s RFA business and the Company’s future financial and operating performance are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Information regarding these risks is included in the Company's filings with the Securities and Exchange Commission.
 
####


 
GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!`@$`2`!(``#_X0@^17AI9@``34T`*@````@`!P$2``,` M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q M``(````4````<@$R``(````4````AH=I``0````!````G````,@```!(```` M`0```$@````!061O8F4@4&AO=&]S:&]P(#7U5F9VAI:FML;6YO8W1U=G=X>7 MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_ MV@`,`P$``A$#$0`_`.0HP&-M++,:OUR\558=]]EMSWG\UN'TIC,K>W_A?1K_ M`.N+>Z=]7\>[.K! MA8?Z:FIB5.QGLPAAOQ3DV,%?0,=Y9FY#&MW.MZQU2QK;L#I^QGKV4[<9C_Z2 MS"Q:/U^O6R6-QL3[*(R&%@;FLQ",=AIZCF_K_`-8' M_K/Z7%_64E.OT;KKA5;:UUF9?8W])=9^C]6S])9EYR]-^LL?\`-WJN[C['D3',>D])3;KS M\&VOU:LBI]>[9O:]I;NC=LW`[=ZA7U3IE@<:\NAX:SU7%MC#%8_PKH=_-_RU MYQ]D]#)Z>RUF,QUKOJ]:QN/6:@ZOULFM[[:G.?OO;9^C]?\`[C^C4BWXF'9; MG=(Q\%M[LWKKV78N.RMEC\+&HQM_@4E/I[WLK;NL<&-$`N<8&I@1@LQNI=0%M+JJW8+6.WTY3QU% MU;ZQD6X^*_J#\3!IPOUBMC/99^TOTGJ^NM*OK%[>J-HR<\]-I&3D?8O2K;&3 M?^T\C"NQGT5M'VIS,3[,QS/YUGVS]H7>I8SUJDI[I]C*QN>X,!(;+C`EQV,; MK^\YVU#NR\7'?4R^ZNI][ME+7N#2]W[E0H4Y+>KT7W-S7='-=-MI99+6=0=7D[+ZJ[*/2Z=E_J]MM'V?/NQ;, MS*^S]&O]/[?3?Z==OZE6DI__T&Z%5TK%Z=GT=.O_`&A]8KF.=UC)M#JS0PN_ M6*_3Z@VG*NV6?TC]'ZEN5Z/VKT?U:I9/4+LTYUC?2+:GV;FNR6T&IEP#?5K: M_,R?V;^U7,_GGY>/=U?_`$_Z;U'K@4DE/H?U2ML/UTZ*R_'RV'==Z-F;:ZSV M^C=O^S,]'&H8WU/I>GZB]G7RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE M\JI)*?I?I/[&^V=2^P;OMGK_`.4/5]7U=\?HOZ7^D^R>G_0_0_4=F_[)_A%I MKY5224_5(B-.$Z^54DE/_]G_[0SX4&AO=&]S:&]P(#,N,``X0DE-!"4````` M`!``````````````````````.$))30/M```````0`$@````!``$`2`````$` M`3A"24T$)@``````#@`````````````_@```.$))300-```````$````>#A" M24T$&0``````!````!XX0DE-`_,```````D```````````$`.$))300*```` M```!```X0DE-)Q````````H``0`````````!.$))30/U``````!(`"]F9@`! M`&QF9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```` M```!`#4````!`"T````&```````!.$))30/X``````!P``#_____________ M________________`^@`````_____________________________P/H```` M`/____________________________\#Z`````#_____________________ M________`^@``#A"24T$`````````@`!.$))300"```````$`````#A"24T$ M"```````$`````$```)````"0``````X0DE-!!X```````0`````.$))300: M``````-)````!@``````````````.0```4\````*`%4`;@!T`&D`=`!L`&4` M9``M`#$````!``````````````````````````$``````````````4\````Y M``````````````````````$`````````````````````````$`````$````` M``!N=6QL`````@````9B;W5N9'-/8FIC`````0```````%)C=#$````$```` M`%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<````Y M`````%)G:'1L;VYG```!3P````9S;&EC97-6;$QS`````4]B:F,````!```` M```%7!E96YU;0````I%4VQI8V54>7!E`````$EM9R`````& M8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P`````` M````3&5F=&QO;F<``````````$)T;VUL;VYG````.0````!29VAT;&]N9P`` M`4\````#=7)L5$585`````$```````!N=6QL5$585`````$```````!-'1415A4`````0``````"6AOD%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N M96YU;0````]%4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O;&]R M5'EP965N=6T````115-L:6-E0D=#;VQO7U5F9VAI:FML;6 MYO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q M(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,7 M9$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S=' M5V=WAY>GM\?_V@`,`P$``A$#$0`_`.0HP&-M++,:OUR\558=]]EMSWG\UN'T MIC,K>W_A?1K_`.N+>Z=]7\>[.K!A8?Z:FIB5.QGLPAAOQ3DV,%?0,=Y9FY#&MW.MZQU2QK;L#I^ MQGKV4[<9C_Z2S"Q:/U^O6R6-QL3[*(R&%@;FLQ",=AIZCF_K_`-8'_K/Z7%_64E.OT;KKA5;:UUF9?8W])=9^C]6S])9EYR]-^LL?\`-WJN[C[' MD3',>D])3;KS\&VOU:LBI]>[9O:]I;NC=LW`[=ZA7U3IE@<:\NAX:SU7%MC# M%8_PKH=_-_RUYQ]D]#)Z>RUF,QUKOJ]:QN/6:@ZOULFM[[:G.?OO;9^C]?\` M[C^C4BWXF'9;G=(Q\%M[LWKKV78N.RMEC\+&HQM_@4E/I[WLK;NL<&-$`N<8 M&I@1@LQNI=0%M+JJ MW8+6.WTY3QU%U;ZQD6X^*_J#\3!IPOUBMC/99^TOTGJ^NM*OK%[>J-HR<\]- MI&3D?8O2K;&3?^T\C"NQGT5M'VIS,3[,QS/YUGVS]H7>I8SUJDI[I]C*QN>X M,!(;+C`EQV,;K^\YVU#NR\7'?4R^ZNI][ME+7N#2]W[E0H4Y+>KT7W-S7='-=-MI99+6=0=7D[+ZJ[*/2Z=E_ MJ]MM'V?/NQ;,S*^S]&O]/[?3?Z==OZE6DI__T&Z%5TK%Z=GT=.O_`&A]8KF. M=UC)M#JS0PN_6*_3Z@VG*NV6?TC]'ZEN5Z/VKT?U:I9/4+LTYUC?2+:GV;FN MR6T&IEP#?5K:_,R?V;^U7,_GGY>/=U?_`$_Z;U'K@4DE/H?U2ML/UTZ*R_'R MV'==Z-F;:ZSV^C=O^S,]'&H8WU/I>GZB]G7RJDDI^JDE\JI)*?JI)?*J22GZ MJ27RJDDI^JDE\JI)*?I?I/[&^V=2^P;OMGK_`.4/5]7U=\?HOZ7^D^R>G_0_ M0_4=F_[)_A%IKY5224_5(B-.$Z^54DE/_]DX0DE-!"$``````%4````!`0`` M``\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(` M90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-P`N`#`````!`#A"24T$!@`````` M!P`"`````0$`_^$22&AT='`Z+R]N&%P+S$N,"\`/#]X M<&%C:V5T(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC M.60G/SX*/#]A9&]B92UX87`M9FEL=&5R&UL;G,Z>#TG861O8F4Z;G,Z;65T82\G('@Z>&%P=&L])UA-4"!T;V]L M:VET(#(N."XR+3,S+"!F&UL;G,Z M6YT87@M M;G,C)R!X;6QN&%P34TZ1&]C=6UE;G1)1#X*(#PO&%P;65T83X*("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`* M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"CP_>'!A8VME M="!E;F0])W$S%F+P)'*"\25#-%.2HK)C<\(U M1">3H[,V%U1D=,/2X@@F@PD*&!F$E$5&I+16TU4H&O+C\\34Y/1E=865I;7% MU>7U9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_(B8J+C(V.CX*3E)66EY MB9FINGM\?7Y_(B8J+C(V.CX.4E9:7F) MF:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P#C]K;W%[+Z%E"] MS+_ON%6D;_@4#-ARODSS3P]2?2YK*/\`WYJ!2Q3_`(.^:W7&3>:O->H<;636 M+Z1)"$2UCGE6,GLJV\3+'_L53%U\DZU&HNM9$&A0R`N)M7E%M(]#OPM:/?RG M_C':OBJE_AN.$!K[7-*M>E56X>\;_N617R?\/E_4O*,#*LVL7EXQ-`EE8*JL M>P66[N8)/B_YA,6*>1]+J7EO?,,RT-(@--LR*;UDE%Q>R`?\8;/)-ID?F8V( MU*!;#R%H#CA^DQ$8KF9#\7&WFF,VK7LO#XD]&:**7^?%4)!Y9L($6[NM!GL; M)]DO/,NJ1V$3;5JEK#;6][+_`-&[SY.O*ODC3+QH&_1MHD,RAXY?J3I%(`:O MZ(UY]3OKI45T//\`1UE`W[%SA1Y=L;!A/YAT>,V]E;U>^_,'S*!-,S*>/^XJ MRD+1>KZ@_=33>K)_NF3E-^Z>;7_FS3O(>C/K-S%,;F_6FGVUZQ;4[]D&US?. MXK:6Z<^26ZHOU6)^/HPS2_4(E4W\T^8O+'Y::.+B.T@2\E!2PL+=$A>=QU)] M-?W<"5_>R<>*?83E(T<;F_DO5;S7/*NE:O?LK75[`)IBB\5Y,2:*O95^RN>3 M-=UW5?,VJRZMJ\QN+RX(4``A46O[N&%-^$2+J?B5M_LMBK),V;-BKLV;-BKLV;-BKLV;-BKLV;- MBKLV;-BKLV;-BKLV;-BKLV;-BKLV;-BKLV;-BKLV;-BKLV;-BKLV;-BKLV;- MBKLV;-BKLV;-BK__T.?/YVUJ&-H-&$&@6[*%9-)B%O(P7<&2\)DOY#X\[K%- M,\EZSJMNVNZK-'I&D2'E)K.J,464G?\`<(W[^\E=?[OTUXR?9]7!IUORCY7/ M#RQ8_IS4T_Z7NK1T@1A^W9:;6@_9>*6[9IHG_89+[3+##'\?Q^E"^*HZ+6_+?E^6.W\F::^L:PS!(M;U.+U M&]4GBOZ.TQ>2HQ?BT$EQZMS_`+K]/#RZTFTT1D\T_FW>2:IK4Z&6Q\L^IRF8 M5/!KUP>%K:\_B]"/]U_QF;U+/`TNO^6OR[B>S\FLFK^92K)=^9YD5H(*CBR: M=$>2-^U^]^-/YI+I/W40_3-,M?(]JOG[S^'O_,EZ3-HFBW#%IC**4N[SGR96 MC^$KS_WD^#_C\]&&W53F\U.72+6U\[?F)&OUQ`#Y0\E1#TX;?@*1W$T-/ADB M4K^\E7_1O^8CT+6WYGP\U_F5YDDD1'U#5+G=^/PPP0@_"*D\+>VBK\/)OB;_ M`'[<2?O#RTT#6O/5Q<>=_.NH#2M")K-JLXIR1:\+;38#4N/]UQ<>:\^7^]5Q MZD;A]>\^00Z<_EGR/;-HOE^G&YG)_P!-O3T:2ZF'Q*C]/25O[OX.7H_Z-&JF M;7WEC\L@T.D&+S#YR4<9=38ES27%DELBV\\R"-W45'-HQ7A MRZ\<59#FS9L5>3:C^8'GV?SOJWE'ROIFGWC:>/53ZQS1S$%AYLSM<11DB2X4 M?",$:#^97F.#S9!Y/\]:1#IUY>@&TN+9B8ZL&]+D"\XD29D:-9(Y?@F_=O%] MOTHD/,:>5_SF\RZD]A=ZD'A-N+>PC$LH+K:/ZA4E?W:^EQ;_`%UQ?3=47\R? MS6TZ_G5=(AT1%,.G73<;R9H2\XI'2G,2.KR1\O@@CY8JRU?/OF6Y\\^8_*.G MV=K,=,L9[C3`0ZR2W*10/!%*[3)%Z;RS\6_NO^,B9&]<_,O\UO+4EG%KF@:= M:27[,EH*F3U&4H&'[F\DX;RI_><<%>6__)]^8_\`F$;_`(A98S\^?][?*/\` MS$7'_$[7%69^3]4_,:]OKA/.FC6NF6*0\H)K>1&9I>0^%N%U<_#PY-]A?];( MAY5_.#5]>\W6FF7=G;0Z'J5QL?H/R/K-XC<9I(#:0$&A$ER1;AE]X_4]7_`&&<@\P:+-Y:_+GR'YEMU_TS M3[H7A`%"3>GZ_$7_`-3ZM!#BKZ+SG'YJ>?\`6O(\FC1Z1;6UP=1%SZHN4D<@ MPF`1B/TI(OM>NW+[7[.="MKF&\MH;NW8/!<(LL3CHR.`RM]*G.3?G"$/FW\O M%D4,AU!PZGH5-S8!@?F,59YY%\QR>;/*UAKMPB1W%P)%N(XJA%DBD:)N(9G8 M*W#FO)OLMG.?*GYQ:[YC\YV>AFSM$TJ^GG6&54E$WH(DLD+9CYBZ=?G5M#TBQN-4T MAWD]552V'+A&Z[<7$L:RH^*O;[F1H;::9:%HT9U!Z54$[YSCRE MYZ\W^;?(>J:]86%I-KUM=&VL;.-66%P$MY&Y^K.IY<9Y?]WQ_97(=Y`\CS^: M=!O/.USJ]ZGF626?ZC>)**!HEH/75E8RQRR\TEBY>G]7_=+PP)Y0E>/\CO-$ ML#M&POZJZ$JPJMCT9:'%7NWE^?6+G1K.?S!;I::M)'6\MHOL(]3\*_'-V_XM M?#+.#:_YBU>R_*KREI6FW4D-[KG[F6Z#L)#$C$,GJ5]1?4DDAYN&_N^:?MX: MZC^6&K^3]0T?6?RY-S2+:`):6[7GU=7GXK7U5;TU5FD>;]XLGJ<(HD MPF_*B_M;;S]K_EWR[?RW?E9;9KBQ21V=`\2L9-Y/4>2K?NQ]GCDI\Q:Y:>6M$O=< MOJF"RCYE%^T[$A(XU_RI9&2-:_S9S+\C/[_S;_S&I^N;.@^=O+S^:_*VHZ#% M*(9KI%,,CUXB6*1)X@]`S>FTD2J_%?L8J\[C\[?FYJ.AR^<-/TG3(M%C22XC MMI/4>=K>*I>3^^B]3@J/^S"\O']U`W).<^\B>;8O.GEV'6EA^KS+4%59621?]?.7:'Y\U[\O=-B\K>?/+D[:;`&MX;V-0RM&Q/[GX_]$NMG MX_!<1_NO@DC=\-_/<7E_6_RNDUGR0([6SM+A+SA81_536OU:Y66.,1E'2.3U M).8_W5&WV>&*O7\V<0\_^9;W6?R\\G6UA.XU37Y+=6,;%6>2*/T9TJIY?[VR MQ8%\X)I@_,'3?*GG&]N+;RE9:?`EG'ZCI%(RIP66=E_FD1XWG_8]-?C1>>*O M>32KR(,<7I_P!S_E_:R->6OR^N5DUO M3++6?6\@ZK$K:<;*[]2XBE22*53"_!X8UVFC=T=_53T?4^/(S^3WEJQNM_9L\Z>7V\I^?QJWF#\P]>6TU"X MN'BTJTDNQ"+2'BLB/#&YX\%,GI+R7TV]%WDYRN[X-T+S%JNI?DQYD@O;J2:X MTN1(;>Z+MZ@A9H71/4KZAX,9`OQ?W7"/]C%7OV;/.>I>4/K/Y66WGF_U2\N- M7M8X#9JTG[F&#ZPMJD4:<>2MZ;>J\JOS>?XL6\Q>5IK[\M[?\QM5U:]N_,"Q MVLL;O(!$D4DT=M''$JJK1.L;K,\JOSDN?4E;^\Q5]#9LX3Y\U[5;CR9Y!.H7 MEQ#I.K)"?,-Y;U$CTC@KR91\3/$UW/Z-.$DD7V/W>";;R9H=O?\`Z:\DZO"W MDMK.:+S3;?79'/H/%(LQ*(LCB00MZG&5DDBD3X,5?__1B'E[R&LNGKYF\XW9 MT/RV*&*1A_I5X3NJ64)#,>:CEZO!O@^...2/G)&SS+Y\:_L#Y<\LVHT+RM&3 M2RB/[ZXVIZE]-5FD9U'QQ\W7_?LEQQ1\(O,7F36/-.HOJFMW)GF-1&GV8HD_ MWW#']F-/^&?[=:_+W\M+C1+6/S7KUDLVJD>KI6FW1]*&UH.7US4'8' MTVC^VD7!Y+?[?I_6O]Y54F\M^6K/R)9VGFCS39O>^8[Q@/+'EA5+3-+U2XGB M`9PZ?"RKP_T;^5KWTHH'ZM;V&AWK>:OS4F76?,]R!):>5H'7THD&\8O''J1Q M6Z5^"#]Y&WQM_IS/-PDE[?W41N]9T2YA2XN/W6H_F'K"B&W"`$BUT&V?FTL7 MV_1]!9(963XY;N5UN,@]C=6*WDO^!](NO-NO%^=QYCU.%YE25O\`=\-F>215 M:DB7.HR>M&_VL54]2M?-_GSAYB\TW4.B:!%\-I/>5@M8T(KPT^TWFNI'3[+( MK>OQ]/ZQ\"+@+_$7ECRP>'E"P_2&HIT\PZL@8JP_;L=/WB@W^.*:X]2=?L.F M,U;3I[V[;4//7FF#Z\0P-O"_Z4NU(-3"L=HPL+9:_P"Z_KD"+_OO`7Z7\JZ: M?]P^AMJ$JFJWFN2^H.E#2PM##`/^>\]YBJ!=O,OG#4GF(O-;U%OME%>=U4FM M.*!A#%7]D<(DSU5Y!LKG3O)NBV-XGIW,%LB31AE?BPK5>499-O\`);/*VI>; M->U*W%E=7[16`'%=/M@EK:!?#ZK;+#`W^S1FSU%^6@X^0O+XI3_0X]OOQ5E6 M;-FQ5XYY5/\`R'GS1_S!/_V(8EYXXVOYV^4[E:1F:&W1F%!R9IKF$U\24=8_ M]7.O1Z9IL-Y)J,-G!'>S`K+=I$BRN#2H>4#FWV$ZM^SE7>E:9?RQ3WUE!C_\0LL9^?)_TWRC_P`Q%Q_Q M.USKT>F:;%>/J,5G`E]*.,MVL2"9AL*-*!S;["?M?LYKS3--U$Q-J%G!=F`E MH3/$DA0FE2G,-P^ROV<5>3_GC=2ZE=>6O)=HP]?4KM9G'=2S"TMRW^0S3SM_ MSRP+YK_*&6P\LZC>1>8M1OA86[7,=C+,S?"V"71)$:.10Z."K*PJ"#L00<583^46 MKC5_(6F58-+8!K"4#]GZN>,*_P#2,8&R,_G#_P`I;^7G_;0?_J)L,ZK9:=I^ MFQ-!IUK#9Q,W-H[>-8E+$!>16,*.7%57EFNM-TZ^E@FO;2&YEMFY6TDT:2-$ MU5;E&S@F-N2(?A_D7%7SY^:.DWD?YBS:-9/Z<'F];!9`!MR,R0#Z4FMEF;_7 MR5>8HXX/SU\I01*$CCTU4C0=`JC4``/D,ZS/IVGW-Q#=W-I#-O#U%;C6G[.";.RL].MTL]/MXK2VCVC@@18 MXU!W^%$"JN*O$_RQ_,#1/+GDJ[TG4Y6AU>QGG^K:>47?+[:B-8;2K,ZF&YB_-O%Z_("G M+UN/JBK*X*NQ_93U88XN7\\J9-_,OYJQS3Z%IGD&YMM2 MU'5KA$D5XWD$43T'[Q5:%HI*MS=9/[N..1I..=)CLK.*U^H16\26?$Q_5E11 M%P;9D],#AQ-?LTP%IWEKR[I$[7.E:196,[#BTUK;10N5/[/*-5;CBKQK4I?+ M]S^<^JI^8#H=-M;=5TR.])^K*WIP/&I!_=^FZMD85D"+:>GZ485>$T#69(YM7 MTNTOY8AQBDNH(YF45KQ5I%8A:]L6;2-*:[@OVL; M:+1F^%6Q5Y5^1?\`?^;?^8U/US9.OS"NO,%AY1U"_P#+,C1:G:A)E9(TE;TD M=3<4259$-(/4;['+X?@P]L]-T[3O4.GV<%IZQY3>A&D?-A7=^`7D=_VL%8J\ MJTO\U_)VH^2$/F>]2XOS:&'4]/>+]Y<2A>#\(T1866Y^VK)^ZC]3X_2X/P"? MDMY?GNOR]U6TU-&2RUN69(@P/QPO;I;23)[.RLJG_BK.C2>3O*4URUY-H.G2 M7+-S:=[2!G+5KS+%.7+_`"LOS+?:UI>DM<>7=,&JWRNBI9>HL(X$T9N3$#X! M^SBKP/\`+>"_UGS?Y>\MZC'^Z\HM?W$D?\K^KS;M^Q?&#.C^9?,F@7?G6?R7 MY[T^RCT86HN=-U.\/%B[B.O&9N(M@S+7>-I$'K2NO&/F[(D*<_CR>ZGHNC:TB1ZQI]MJ"1$ MF);J&.8(6ZE/55N-:?LXJ\?_`"QAL;/\S?,%EY/G>X\JI;7UWT(_7K3C7UN/J5X_#]K%7AOY:'R'HNF:UI'GZTTY=8TR[D+?I& M"*24Q+&D?I6YE1GE*RQ2LL,/+^\YHO[S#&/46U?\G/,FJ_H.QT.WN)%6VBT^ M`6Z3)')"IF<#9SZG.'G_`,59US4/+/EO5K@7>J:/97UR`%$]S;12O0=!SD1F MH,'2V5G/:FQGMXI;0J$-LZ*T7%:<5],CAQ6FPIBKR"__`/6>HS_R[6W_`%'1 MX_7B/^A?(#7;ZGIV_P#T=V^=8.EZ:UC^C&LX#84`^IF)##0'F!Z5/3^W\7V? MM9;Z9ILEB-,DLX&L`%46;1(8:*0RCTB/3HK#DOPXJ\FE\U0>7_)GD*PU;3;> M^\OZQ;00:G-=(9(X5182&X<61SP>255^U^X;AD:UFP\D6/GW0T\DW44EE=K, M/,44$YEM$L33ZWSF+,JQ-9_6FGC]7TX?2B?]UG?)M*TNYL1I=Q8V\VGA0@LI M(D:`*OV5]%@8^*_L_#@:T\L>6]/AN+>QT>RMH;M&ANHX;:*-98V%&CE"*/41 M@?LOBK__TCC\J?RI^H>AYI\T0_Z;M+ING2#^X[K<7"G_`(^/VHHF_P!YO[R3 M_2?]YI;YRU9I4-O!;O/"E&]4VTEW`64_:"N;72G=#Q>)[W4?W$T?/ZG\/+)7 MK7_'+NO]3^(SQ]YQ_P"4@DQ5GNL7T=W>/?W[:9<7J%E6_P#,FJ1:I(JG]F'2 MM'$MG;+R^+T3;7"X0:IJD&I0+;ZUYON+RV0*%L-+L9!:*!T"6UP^CVZ4_F6W MR'9L53WU_)MN5]*QU*_IU,]U!:(?G#%;W;_\#=97Z?L(238^7=.A/[,D_P!: MNW^E;FY>V/\`TC81YL53T>327%Q+:HTL\S-)([&M6=W)9F_UL\A9ZY_+3_E`M`_YA$_CBK* MLV;-BKLV;-BKLV;-BKLV;-BKLV;-BKLV;-BKLV;-BKLV;-BKLV;-BKLV;-BK BLV;-BKLV;-BKLV;-BKLV;-BKLV;-BKLV;-BKLV;-BK__V3\_ ` end
-----END PRIVACY-ENHANCED MESSAGE-----